Cell therapy biotech Quell adds $156M for alternative to organ transplant meds

Quell Therapeutics' $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress comes as the field of Treg cell therapy research becomes increasingly competitive.